WELCOME and THANK YOU Sponsors
and to the Sponsors Exhibiting
at this amazing event!
Dr. Carl Flatley, DDS; Sepsis Alliance
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
♦
WELCOME
To the 4th Annual International
Raising C. diff. Awareness
Conference & Health EXPO
September 20, 2016
DoubleTree by Hilton - Atlanta Airport Hotel
……………………………………..
Dr. Clifford McDonald, MD;”Our Ongoing Battle Against C. diff.; A Status Update 2016″
…………………………………
Dr. Charles Darkoh, PhD; “Targeting Toxin Production and Toxin Activity as a Novel Non-Antibiotic Therapy for Clostridium difficile Infections”
………………………………………………………..
Dr. Lewis, MD and Dr. Immergluck, MD; “Applying Fecal Microbiota Transplantation (FMT) to Treat Recurrent CDI in Children”
Dr. Lewis, MD and Dr. Immergluck, MD; “Applying Fecal Microbiota Transplantation (FMT) to Treat Recurrent CDI in Children”
………………………………………
Dr. David Cook, PhD; “Taking the Next Giant Step: Designed Microbiome-based Drugs For Clostridium difficile Infections”
……………………………………………..
Dr. Mark Wilcox, MD; “Clostridium diffiicle Infection In the Community Setting”
……………………………
………………………………
Dr. Jean de Gunzburg, PhD; “DAV132: A Novel Product Destined To Prevent Antibiotic-Induced CDI”
……………………………….
Barley Chironda, RPN, CIC; “The C. diff. Disinfection Debate: To Use or Not To Use Sporicidal Disinfectants Every-Time In Healthcare Facilities”
…………………………………….
Sushma Shivaswamy, PhD; “True Human ™ Antibody Therapy Against C. difficile.”
………………………………………..
Rachel Sparks ; Evidenced Best Practices For Stopping C. diff. In the Healthcare Environment”
…………………………………….
Dr. Arjun Srinivasan, MD; “Antibiotic Stewardship - Improving Antibiotic Use To Combat C. difficile”
Dr. Arjun Srinivasan, MD 
…………………………
Dr. Joseph Sliman, MD; “Ribaxamase: Protection Of the Gut Microbiome and Prevention Of CDI”
Dr. Joseph Sliman, MD 
..
………………………….
Dr. Dale Gerding, MD; Clostridium difficile Infection In Infants and Children; Diagnostic Pitfalls and Treatment”
Dr. Dale Gerding, MD 
.
.
……………………….
Dr. Stuart Johnson, MD; “Evolving Management of CDI Since Publication Of the Treatment Guidelines”
Dr. Stuart Johnson, MD
……………………..
Dr. Richard Vickers, PhD; Ridinilazole, a Microbiome Preserving Antibiotic For the Treatment Of a C. difficile Infection”
Dr. Richard Vickers, PhD 
……………………..
……………………….
C. diff. Survivors Share Their Journey
Nancy Sheridan
.
Roy Poole 
Veronica Edmond 
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Mary Beth Dorr, Phd; Bezlotoxumab Shows Efficacy In Preventing Recurrent C. difficile Infection (rCDI) In Patients At High Risk Of Recurrence”
.
………………………
Dr. Hudson Garrett, Jr, PhD; “Reaching Across Disciplines To Reduce the Incidence Of
C. difficile Infection and Other Super-bugs”
………………………
Dr. Simon M. Cutting, PhD; “Thwarting the Opportunist: An Anti-adhesion Vaccine That Prevents C. difficult Colonization”
……………………………..
Dr. Clifford McDonald, MD with C. diff. Survivors — Roy Poole, Nancy C. Caralla, Veronica Edmund, and Nancy Sheridan
C. diff. Survivors; Roy Poole, Nancy Sheridan, Veronica Edmund, Nancy C Caralla
…………………………
Kathy Leith, MBA; “Blazing the Trail for Patients With Microbiota Restoration”
Thanking you for joining us and we look forward to meeting you again next year on September 11th and 12th in Las Vegas, NV
